151 related articles for article (PubMed ID: 20428297)
1. What is the true mortality benefit of prostate-specific antigen screening?
Loeb S; Partin AW
Rev Urol; 2010; 12(1):66-7. PubMed ID: 20428297
[No Abstract] [Full Text] [Related]
2. Prostate Specific Antigen and Biopsy Contamination in the Göteborg-1 Randomized, Population-Based, Prostate Cancer Screening Trial.
Stinesen Kollberg K; Holmberg E; Josefsson A; Hugosson J; Arnsrud Godtman R
J Urol; 2022 Nov; 208(5):1018-1027. PubMed ID: 35771961
[TBL] [Abstract][Full Text] [Related]
3. Estimate of Opportunistic Prostate Specific Antigen Testing in the Finnish Randomized Study of Screening for Prostate Cancer.
Kilpeläinen TP; Pogodin-Hannolainen D; Kemppainen K; Talala K; Raitanen J; Taari K; Kujala P; Tammela TLJ; Auvinen A
J Urol; 2017 Jul; 198(1):50-57. PubMed ID: 28104375
[TBL] [Abstract][Full Text] [Related]
4. A System Dynamics Model of Serum Prostate-Specific Antigen Screening for Prostate Cancer.
Palma A; Lounsbury DW; Schlecht NF; Agalliu I
Am J Epidemiol; 2016 Feb; 183(3):227-36. PubMed ID: 26702631
[TBL] [Abstract][Full Text] [Related]
5. A Detailed Evaluation of the Effect of Prostate-specific Antigen-based Screening on Morbidity and Mortality of Prostate Cancer: 21-year Follow-up Results of the Rotterdam Section of the European Randomised Study of Screening for Prostate Cancer.
de Vos II; Meertens A; Hogenhout R; Remmers S; Roobol MJ;
Eur Urol; 2023 Oct; 84(4):426-434. PubMed ID: 37029074
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection.
Ross KS; Carter HB; Pearson JD; Guess HA
JAMA; 2000 Sep; 284(11):1399-405. PubMed ID: 10989402
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen and prostate cancer mortality: a systematic review.
Wallner LP; Jacobsen SJ
Am J Prev Med; 2013 Sep; 45(3):318-26. PubMed ID: 23953359
[TBL] [Abstract][Full Text] [Related]
8. New Evidence for the Benefit of Prostate-specific Antigen Screening: Data From 400,887 Kaiser Permanente Patients.
Alpert PF
Urology; 2018 Aug; 118():119-126. PubMed ID: 29772218
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer.
Shteynshlyuger A; Andriole GL
J Urol; 2011 Mar; 185(3):828-32. PubMed ID: 21239021
[TBL] [Abstract][Full Text] [Related]
10. Controversies in prostate cancer screening.
Murphy AM; McKiernan JM; Olsson CA
J Urol; 2004 Nov; 172(5 Pt 1):1822-4. PubMed ID: 15540729
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen-based screening: controversy and guidelines.
Kim EH; Andriole GL
BMC Med; 2015 Mar; 13():61. PubMed ID: 25857320
[TBL] [Abstract][Full Text] [Related]
12. Assessment of prostate-specific antigen screening: an evidence-based report by the German Institute for Quality and Efficiency in Health Care.
Paschen U; Sturtz S; Fleer D; Lampert U; Skoetz N; Dahm P
BJU Int; 2022 Mar; 129(3):280-289. PubMed ID: 33961337
[TBL] [Abstract][Full Text] [Related]
13. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.
Arnsrud Godtman R; Holmberg E; Lilja H; Stranne J; Hugosson J
Eur Urol; 2015 Sep; 68(3):354-60. PubMed ID: 25556937
[TBL] [Abstract][Full Text] [Related]
14. Recent Changes in Prostate Cancer Screening Practices and Epidemiology.
Lee DJ; Mallin K; Graves AJ; Chang SS; Penson DF; Resnick MJ; Barocas DA
J Urol; 2017 Dec; 198(6):1230-1240. PubMed ID: 28552708
[TBL] [Abstract][Full Text] [Related]
15. An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States.
Shaw PA; Etzioni R; Zeliadt SB; Mariotto A; Karnofski K; Penson DF; Weiss NS; Feuer EJ
Am J Epidemiol; 2004 Dec; 160(11):1059-69. PubMed ID: 15561985
[TBL] [Abstract][Full Text] [Related]
16. Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality: 24-Year Follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial.
Carlsson SV; Arnsrud Godtman R; Pihl CG; Vickers A; Lilja H; Hugosson J; Månsson M
Eur Urol; 2023 Feb; 83(2):103-109. PubMed ID: 36334968
[TBL] [Abstract][Full Text] [Related]
17. Screening for prostate cancer.
Ilic D; Neuberger MM; Djulbegovic M; Dahm P
Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Arm.
Halpern JA; Shoag JE; Mittal S; Oromendia C; Ballman KV; Hershman DL; Wright JD; Shih YT; Nguyen PL; Hu JC
J Urol; 2017 Feb; 197(2):363-368. PubMed ID: 27569432
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
Bokhorst LP; Bangma CH; van Leenders GJ; Lous JJ; Moss SM; Schröder FH; Roobol MJ
Eur Urol; 2014 Feb; 65(2):329-36. PubMed ID: 23954085
[TBL] [Abstract][Full Text] [Related]
20. The routine use of prostate-specific antigen for early detection of cancer prostate in India: Is it justified?
Dubey D
Indian J Urol; 2009 Apr; 25(2):177-84. PubMed ID: 19672341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
